SCHEMBL3871759

SCHEMBL3871759

Cc1c2n(c3cc(C(=O)OC4CCCCC4)ccc13)C(O)c1ccccc1-2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
HTT P42858 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
JMJD6 Q6NYC1 1/20 0.36
STS P08842 3/20 0.36
SCN1A P35498 2/20 0.36
SCN2A Q99250 2/20 0.36
SCN3A Q9NY46 2/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
RXFP1 Q9HBX9 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13841666 0.79 ALDH1A1 (0.43) SMN1; SMN2HTTL3MBTL1LMNANPSR1
SCHEMBL3242888 0.79 ALDH1A1 (0.43) SMN1; SMN2HTTL3MBTL1LMNANPSR1
SCHEMBL11893100 0.75 PRKCA (0.42)
SCHEMBL772511 0.74 PRKCA (0.49) L3MBTL1
SCHEMBL3242890 0.72 MEN1 (0.42) L3MBTL1MAPTLMNANPSR1MEN1
SCHEMBL772512 0.68 ALDH1A1 (0.37) KMT2AKDM4EALDH1A1
SCHEMBL3871757 0.67 KMT2A (0.37) SMN1; SMN2RAB9ALMNANPSR1MEN1
SCHEMBL11864448 0.67 SMN1; SMN2 (0.51) SMN1; SMN2HTTNPC1RAB9AL3MBTL1
SCHEMBL9396750 0.66 MAPT (0.51) SMN1; SMN2HTTNPC1RAB9AL3MBTL1
SCHEMBL14253440 0.66 SCN9A (0.41) SMN1; SMN2HTTL3MBTL1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099804-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Brystol-Myers Squibb Company (US) 2009-09-16 EP disclosed
EP-2029606-A2 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS Brystol-Myers Squibb Company (US) 2009-03-04 EP disclosed
WO-2008089027-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2008-07-24 WO disclosed
WO-2007140254-A2 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-06 WO disclosed